What is Glioblastoma Multiforme?
Glioblastoma multiforme is one of the most malignant tumors among all brain tumors. In general, glioblastoma multiforme is treated with radiotherapy and chemotherapy after surgical removal of the tumor, but the prognosis is very poor so it is urgent to develop new treatments.
Development stage
· OKN-007: Disufenton Sodium, Nitrone derivatives for the treatment of glioblastoma multiforme
· Completed recruitment of Phase 1b clinical trial to patients with recurrent glioblastoma multiforme using OKN-007
· Ongoing Phase 1 clinical trial of the combination therapy with OKN-007 and temozolomide in patients with newly diagnosed glioblastoma multiforme as an investigator-
initiated trial
· Preparing Phase 2 clinical trial of the combination therapy with OKN-007 and temozolomide in patients with recurrent glioblastoma multiforme
· Designated as an orphan drug for the a treatment of glioblastoma multiforme by the US FDA
Clinical Information
Phase 1 : https://clinicaltrials.gov/ct2/show/NCT01672463
For clinical papers: https://clinicaltrials.gov/ct2/show/NCT03587038?term=OKN-007&draw=2&rank=3
Published paper related to efficacy in glioblastoma: https://www.ncbi.nlm.nih.gov/pubmed/25920494
Published paper related to HIF-1α Inhibition: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578492/
Published paper related to inhibition of tumor cell proliferation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190608/
Published paper related to inhibition of angiogenesis: https://www.ncbi.nlm.nih.gov/pubmed/26269774
Phase 2 : https://clinicaltrials.gov/ct2/show/NCT04388475?cond= NCT04388475&draw=2&rank=1
Phase 1b(Oral Study): https://www.clinicaltrials.gov/ct2/show/NCT05561374
